Market Overview

Morgan Stanley Considers Key Issues for Catamaran Ahead of CFO Meeting

UPDATE: Morgan Stanley Reiterates Equal-Weight Rating on Catamaran Corp Following Salveo Acquisition
Catamaran To acquire Salveo Specialty Pharmacy For $260M In Cash
Catamaran sinks on outlook (Investor's Business Daily)

In a report published Tuesday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Equal-Weight rating on Catamaran (NASDAQ: CTRX).

In the report, Morgan Stanley noted, “We are hosting Mark Shapiro, CTRX's recently appointed CFO, on Wednesday 4/9 at 2pm ET, as the first guest speaker in our annual CEO/CFO conference call series. On the call we will look to discuss the key investor debates, outlined below.”

Catamaran closed on Monday at $41.68.

Latest Ratings for CTRX

Feb 2015Deutsche BankMaintainsHold
Feb 2015Leerink SwannMaintainsOutperform
Feb 2015BarclaysMaintainsEqualweight

View More Analyst Ratings for CTRX
View the Latest Analyst Ratings

Posted-In: Morgan Stanley Ricky R. GoldwasserAnalyst Color Reiteration Analyst Ratings


Related Articles (CTRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters